Sentia Medical Sciences and Neurocrine Biosciences Extend Research Collaboration to Discover Novel CRF Peptides
16 Aprile 2024 - 10:01PM
Sentia Medical Sciences Inc. today announced that they have further
extended a research collaboration with Neurocrine Biosciences, Inc.
(Nasdaq: NBIX) aimed at discovering novel, long-acting
corticotropin-releasing factor (CRF) receptor antagonist peptide
therapeutics. The collaboration will continue to leverage Sentia’s
proprietary peptide-based platform and Neurocrine’s drug
development expertise in CRF biology to develop and commercialize
medicines with the potential to treat a variety of
hypothalamic-pituitary-adrenal (HPA) axis modulated diseases.
Under the terms of the research collaboration
extension, Sentia and Neurocrine will continue to work together to
discover novel peptide antagonists targeting CRF and advance them
to development candidate stage, after which Neurocrine would be
solely responsible for all further development, manufacturing,
regulatory and commercial activities. As part of the collaboration,
Sentia will continue to receive committed research funding from
Neurocrine to support discovery efforts. Sentia is eligible to
receive milestone and royalty payments based on products developed
from this collaboration.
“We are delighted to further extend this important
collaboration focused on the discovery and development of novel
peptide therapeutics to address HPA-driven diseases and other
potential indications with disrupted CRF physiology” said Dominic
P. Behan, Ph.D., D.Sc., Chief Executive Officer of Sentia Medical
Sciences.
About Sentia Medical
SciencesSentia Medical Sciences Inc. is a privately held
company with a vision to be a world leader in the development of
novel peptide therapeutics to manage and cure stress-related
diseases (www.sentiamedical.com).
Sentia Medical Sciences Inc.
info@sentiamedical.com
www.sentiamedical.com
Grafico Azioni Neurocrine Biosciences (NASDAQ:NBIX)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Neurocrine Biosciences (NASDAQ:NBIX)
Storico
Da Giu 2023 a Giu 2024